Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
More News
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Oversold Conditions For Lenz Therapeutics (LENZ)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
HC Wainwright Expects Weaker Earnings for LENZ Therapeutics
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for LENZ Therapeutics in a research note issued to investors on Tuesday, April...
MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm...
MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Price Target Cut to $48.00 by Analysts at HC Wainwright
HC Wainwright reduced their target price on LENZ Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday...
MarketBeat
Aberdeen Group plc Increases Holdings in LENZ Therapeutics, Inc. $LENZ
Aberdeen Group plc lifted its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 274.4% during the fourth quarter, according to the company in its most recent filing with...
MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. One...
MarketBeat
HC Wainwright Issues Positive Forecast for LENZ Earnings
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for LENZ Therapeutics in a report issued on...
MarketBeat
<
1
2
>

Advertisement|Remove ads.